Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 8/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17027210 | 0.92 | S1PR5 (0.53) | PTGER1RXRARXRBRXRGPTGDR2 | |
| SCHEMBL18580782 | 0.87 | PTGDR2 (0.45) | PTGER1PTGDR2 | |
| SCHEMBL18581366 | 0.86 | PTGDR2 (0.48) | PTGDR2 | |
| SCHEMBL17034159 | 0.86 | S1PR1 (0.50) | PTGER1RXRARXRBRXRGPTGDR2 | |
| SCHEMBL17034083 | 0.85 | S1PR5 (0.53) | PTGER1RXRARXRBRXRGPTGDR2 | |
| SCHEMBL17034172 | 0.85 | MRGPRX4 (0.48) | PTGER1RXRARXRBRXRGPTGDR2 | |
| SCHEMBL17034174 | 0.84 | S1PR5 (0.55) | PTGER1RXRARXRBRXRGPTGDR2 | |
| SCHEMBL17034162 | 0.83 | CYP11B1 (0.52) | PTGER1RXRARXRBRXRGPTGDR2 | |
| SCHEMBL17034082 | 0.82 | S1PR5 (0.47) | PTGER1RXRARXRBRXRGPTGDR2 | |
| SCHEMBL17034177 | 0.82 | NOTUM (0.51) | PTGER1PTGDR2S1PR1S1PR5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | PTGER1 190/4885RXRA 257/4885RXRB 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.